Clinical Trial

A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and ADA of MIL62 compared with placebo in participants with systemic lupus erythematosus.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-03-21; most recent amendment 2025-12-14.
Status change: Recruiting → Active, Not Recruiting 2025-12-14
Status change: Not Yet Recruiting → Recruiting 2023-08-09
Trial Details
NCT Number NCT05796206
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions Systemic Lupus Erythematosus
Enrollment 120 participants
Start Date 2023-05-26
Primary Completion 2026-02 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-19